{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:54:45Z","timestamp":1781639685591,"version":"3.54.5"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"HOPE T32 Training","award":["AI007384"],"award-info":[{"award-number":["AI007384"]}]},{"name":"San Diego Center for AIDS Research","award":["P30 AI036214"],"award-info":[{"award-number":["P30 AI036214"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,16]]},"DOI":"10.1093\/infdis\/jiag058","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T12:34:47Z","timestamp":1769949287000},"page":"977-980","source":"Crossref","is-referenced-by-count":0,"title":["Immune Checkpoint Inhibition Therapy Beyond the Tumor: Implications for Hepatitis B Virus in Hepatocellular Carcinoma"],"prefix":"10.1093","volume":"233","author":[{"given":"Renato","family":"Bobadilla","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, University of California San Diego , San Diego, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4712-2657","authenticated-orcid":false,"given":"Arthur Y","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"2026061615203915900_jiag058-B1","doi-asserted-by":"crossref","DOI":"10.54394\/CJQU6666","volume-title":"Global hepatitis report 2024: action for access in low- and middle-income countries","author":"World Health Organization","year":"2024"},{"key":"2026061615203915900_jiag058-B2","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/hep.22881","article-title":"Hepatitis B: the virus and disease","volume":"49","author":"Liang","year":"2009","journal-title":"Hepatology"},{"key":"2026061615203915900_jiag058-B3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/vaccines5030024","article-title":"Immune evasion strategies during chronic Hepatitis B and C virus infection","volume":"5","author":"Ortega-Prieto","year":"2017","journal-title":"Vaccines (Basel)"},{"key":"2026061615203915900_jiag058-B4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New approaches to chronic hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N Engl J Med"},{"key":"2026061615203915900_jiag058-B5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/1744666X.2023.2198209","article-title":"The CD8+ T cell exhaustion mechanisms in chronic hepatitis B infection and immunotherapeutic strategies: a systematic review","volume":"19","author":"Allahmoradi","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"2026061615203915900_jiag058-B6","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3390\/v15051141","article-title":"The role of CTLA-4 in T cell exhaustion in chronic hepatitis B virus infection","volume":"15","author":"Apol","year":"2023","journal-title":"Viruses"},{"key":"2026061615203915900_jiag058-B7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/labinvest.2011.157","article-title":"HBcAg induces PD-1 upregulation on CD4+ T cells through activation of JNK, ERK and PI3K\/AKT pathways in chronic hepatitis-B-infected patients","volume":"92","author":"Li","year":"2012","journal-title":"Lab Invest"},{"key":"2026061615203915900_jiag058-B8","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/eji.201141852","article-title":"Blockade of Tim-3 signaling restores the virus-specific CD8\u207a T-cell response in patients with chronic hepatitis B","volume":"42","author":"Wu","year":"2012","journal-title":"Eur J Immunol"},{"key":"2026061615203915900_jiag058-B9","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J Hepatol"},{"key":"2026061615203915900_jiag058-B10","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2024.06.027","article-title":"Phase Ib\/IIa randomized study of heterologous ChAdOx1-HBV\/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB","volume":"81","author":"Tak","year":"2024","journal-title":"J Hepatol"},{"key":"2026061615203915900_jiag058-B11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jhep.2024.07.018","article-title":"Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy","volume":"82","author":"Mon","year":"2025","journal-title":"J Hepatol"},{"key":"2026061615203915900_jiag058-B12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/hepr.13798","article-title":"Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection","volume":"52","author":"Hagiwara","year":"2022","journal-title":"Hepatol Res"},{"key":"2026061615203915900_jiag058-B13","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.14309\/ajg.0000000000001142","article-title":"Hepatitis flare during immunotherapy in patients with current or past hepatitis B virus infection","volume":"116","author":"Wong","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"2026061615203915900_jiag058-B14","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3390\/v14020434","article-title":"Current trend in antiviral therapy for chronic hepatitis B","volume":"14","author":"Chien","year":"2022","journal-title":"Viruses"},{"key":"2026061615203915900_jiag058-B15","doi-asserted-by":"crossref","first-page":"892618","DOI":"10.3389\/fimmu.2022.892618","article-title":"Correlation of HBV DNA and hepatitis B surface antigen levels with tumor response, liver function and immunological indicators in liver cancer patients with HBV infection undergoing PD-1 inhibition combinational therapy","volume":"13","author":"Pan","year":"2022","journal-title":"Front Immunol"},{"key":"2026061615203915900_jiag058-B16","doi-asserted-by":"crossref","first-page":"1480520","DOI":"10.3389\/fimmu.2024.1480520","article-title":"The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients","volume":"15","author":"Ji","year":"2024","journal-title":"Front Immunol"},{"key":"2026061615203915900_jiag058-B17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"key":"2026061615203915900_jiag058-B18","doi-asserted-by":"crossref","first-page":"e39179","DOI":"10.1371\/journal.pone.0039179","article-title":"PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model","volume":"7","author":"Tzeng","year":"2012","journal-title":"PLoS One"},{"key":"2026061615203915900_jiag058-B19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/HEP.0000000000001202","article-title":"Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibition","volume":"82","author":"Urbanek-Quaing","year":"2025","journal-title":"Hepatology"},{"key":"2026061615203915900_jiag058-B20","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026061615203915900_jiag058-B21","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/thoraxjnl-2021-217260","article-title":"Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy","volume":"77","author":"Morelli","year":"2022","journal-title":"Thorax"},{"key":"2026061615203915900_jiag058-B22","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41416-025-02978-7","article-title":"Prompt initiation of durvalumab and tremelimumab for unresectable hepatocellular carcinoma in patients with chronic active hepatitis B: a phase 2 clinical trial","volume":"132","author":"Shao","year":"2025","journal-title":"Br J Cancer"},{"key":"2026061615203915900_jiag058-B23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hep.31026","article-title":"Pregenomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis B e antigen-negative chronic hepatitis B patients suppressed on nucleos(T)ide analogue therapy","volume":"72","author":"Carey","year":"2020","journal-title":"Hepatology"},{"key":"2026061615203915900_jiag058-B24","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1002\/hep.32018","article-title":"Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America","volume":"74","author":"Ghany","year":"2021","journal-title":"Hepatology"},{"key":"2026061615203915900_jiag058-B25","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1097\/HEP.0000000000000413","article-title":"Use of HBV RNA and to predict change in serological status and disease activity in CHB","volume":"78","author":"Ghany","year":"2023","journal-title":"Hepatology"},{"key":"2026061615203915900_jiag058-B26","doi-asserted-by":"crossref","first-page":"10141","DOI":"10.3390\/ijms262010141","article-title":"Utility of Serum HBV RNA measurement during nucleoside\/nucleotide analog therapy in chronic hepatitis B patients","volume":"26","author":"Hiraoka","year":"2025","journal-title":"Int J Mol Sci"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag058\/66738679\/jiag058.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/6\/977\/66738679\/jiag058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/6\/977\/66738679\/jiag058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:20:46Z","timestamp":1781637646000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/233\/6\/977\/8457539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,2,4]]},"published-print":{"date-parts":[[2026,6,16]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag058","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,15]]},"published":{"date-parts":[[2026,2,4]]}}}